Conditions: Pancreatic Cancer
Keywords: insulinoma cancer of pancreas neoplasms, pancreas alpha-cell tumor glucagonoma beta-cell tumor somatostatinoma
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 7
Healthy volunteers: no

Brief summary:
Cancer results from multiple mutations which cause cells to grow uncontrolled. It therefore may be necessary to inhibit several oncogenic targets to affect cancer cell growth. Studies have shown that panobinostat (LH589) causes a wide range of effect on endothelial cells that lead to inhibition of tumor angiogenesis (a fundamental step in the transition of tumors from a dormant state to a malignant one). Bortezomib triggers cell death in pancreatic cancer cells but the mechanism is not well defined but has been determined to be cytostatic. Combining these two drugs may work together in the treatment of pancreatic cancer.

Detailed description:

Arms:
arm 1: Pancreatic cancer patients who received treatment with bortezomib and panobinostat after progressing on gemcitabine.

Interventions: intervention 1: Bortezomib intervention 2: Panobinostat
Intervention descriptions: intervention 1: 1.3 mg/m\^2 administered intravenously twice daily on days 1 and 8 for 2 weeks followed by 10 day rest period intervention 2: 20 milligrams administered orally 3 times weekly for 2 weeks on Days 1,3,5,8,10 and 12 followed by 9 day rest period

Protocol document: